SANARA MEDTECH INC (SMTI)

US79957L1008 - Common Stock

34.94  +0.83 (+2.43%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SMTI. SMTI was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While SMTI seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, SMTI is valued expensive at the moment.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

SMTI had negative earnings in the past year.
SMTI had a negative operating cash flow in the past year.
SMTI had negative earnings in each of the past 5 years.
SMTI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of SMTI (-9.45%) is better than 60.43% of its industry peers.
Looking at the Return On Equity, with a value of -21.02%, SMTI is in the better half of the industry, outperforming 60.96% of the companies in the same industry.
Industry RankSector Rank
ROA -9.45%
ROE -21.02%
ROIC N/A
ROA(3y)-13.53%
ROA(5y)-22.04%
ROE(3y)-18.14%
ROE(5y)-33.57%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

SMTI's Gross Margin of 90.16% is amongst the best of the industry. SMTI outperforms 98.93% of its industry peers.
SMTI's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SMTI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.63%
GM growth 5Y-0.75%

More info and screens

4

2. Health

2.1 Basic Checks

SMTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SMTI has more shares outstanding
SMTI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SMTI is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 4.06 indicates that SMTI is not in any danger for bankruptcy at the moment.
SMTI's Altman-Z score of 4.06 is fine compared to the rest of the industry. SMTI outperforms 73.26% of its industry peers.
SMTI has a Debt/Equity ratio of 0.76. This is a neutral value indicating SMTI is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.76, SMTI is not doing good in the industry: 73.26% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF N/A
Altman-Z 4.06
ROIC/WACCN/A
WACC9.09%

2.3 Liquidity

SMTI has a Current Ratio of 2.23. This indicates that SMTI is financially healthy and has no problem in meeting its short term obligations.
SMTI has a Current ratio of 2.23. This is in the lower half of the industry: SMTI underperforms 62.03% of its industry peers.
SMTI has a Quick Ratio of 2.02. This indicates that SMTI is financially healthy and has no problem in meeting its short term obligations.
SMTI's Quick ratio of 2.02 is in line compared to the rest of the industry. SMTI outperforms 49.73% of its industry peers.
Industry RankSector Rank
Current Ratio 2.23
Quick Ratio 2.02

More info and screens

6

3. Growth

3.1 Past

SMTI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.79%.
Looking at the last year, SMTI shows a very strong growth in Revenue. The Revenue has grown by 24.67%.
Measured over the past years, SMTI shows a very strong growth in Revenue. The Revenue has been growing by 61.91% on average per year.
EPS 1Y (TTM)-13.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.54%
Revenue 1Y (TTM)24.67%
Revenue growth 3Y60.94%
Revenue growth 5Y61.91%
Sales Q2Q%35.24%

3.2 Future

The Earnings Per Share is expected to decrease by -14.24% on average over the next years. This is quite bad
SMTI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.49% yearly.
EPS Next Y-178.54%
EPS Next 2Y-52.14%
EPS Next 3Y-14.24%
EPS Next 5YN/A
Revenue Next Year29.78%
Revenue Next 2Y24.63%
Revenue Next 3Y20.49%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SMTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SMTI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

SMTI's earnings are expected to decrease with -14.24% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-52.14%
EPS Next 3Y-14.24%

More info and screens

0

5. Dividend

5.1 Amount

SMTI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SANARA MEDTECH INC

NASDAQ:SMTI (12/24/2024, 7:38:22 PM)

34.94

+0.83 (+2.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners8.6%
Inst Owner Change10.96%
Ins Owners7.62%
Ins Owner Change0.03%
Market Cap305.38M
Analysts82.86
Price Target44.88 (28.45%)
Short Float %6.55%
Short Ratio6.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-22.59%
Min EPS beat(2)-91.41%
Max EPS beat(2)46.24%
EPS beat(4)2
Avg EPS beat(4)-40.48%
Min EPS beat(4)-194.12%
Max EPS beat(4)77.38%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.06%
Min Revenue beat(2)2.64%
Max Revenue beat(2)3.47%
Revenue beat(4)3
Avg Revenue beat(4)2.36%
Min Revenue beat(4)-1.77%
Max Revenue beat(4)5.11%
Revenue beat(8)4
Avg Revenue beat(8)-2.52%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)45.71%
EPS NQ rev (3m)-171.43%
EPS NY rev (1m)30.05%
EPS NY rev (3m)30.05%
Revenue NQ rev (1m)4.19%
Revenue NQ rev (3m)10.89%
Revenue NY rev (1m)2.35%
Revenue NY rev (3m)2.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.91
P/FCF N/A
P/OCF N/A
P/B 7.68
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.99
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS8.93
BVpS4.55
TBVpS-0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.45%
ROE -21.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.16%
FCFM N/A
ROA(3y)-13.53%
ROA(5y)-22.04%
ROE(3y)-18.14%
ROE(5y)-33.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.63%
GM growth 5Y-0.75%
F-Score5
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.28%
Cap/Sales 0.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.23
Quick Ratio 2.02
Altman-Z 4.06
F-Score5
WACC9.09%
ROIC/WACCN/A
Cap/Depr(3y)54.62%
Cap/Depr(5y)430.88%
Cap/Sales(3y)1.72%
Cap/Sales(5y)6.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.54%
EPS Next Y-178.54%
EPS Next 2Y-52.14%
EPS Next 3Y-14.24%
EPS Next 5YN/A
Revenue 1Y (TTM)24.67%
Revenue growth 3Y60.94%
Revenue growth 5Y61.91%
Sales Q2Q%35.24%
Revenue Next Year29.78%
Revenue Next 2Y24.63%
Revenue Next 3Y20.49%
Revenue Next 5YN/A
EBIT growth 1Y6.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.07%
OCF growth 3YN/A
OCF growth 5YN/A